Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors

Last updated: March 26, 2024
Sponsor: Erasmus Medical Center
Overall Status: Active - Recruiting

Phase

N/A

Condition

Head And Neck Cancer

Thymomas

Carcinoma

Treatment

Recurrence Prediction Tool

Artificial Intelligence Diagnostics

Clinical Study ID

NCT06301945
Maastro Clinic
72725524
  • All Genders

Study Summary

Thymic epithelial tumors are rare neoplasms in the anterior mediastinum. The cornerstone of the treatment is surgical resection. Administration of postoperative radiotherapy is usually indicated in patients with more extensive local disease, incomplete resection and/or more aggressive subtypes, defined by the WHO histopathological classification.

In this classification thymoma types A, AB, B1, B2, B3, and thymic carcinoma are distinguished. Studies have shown large discordances between pathologists in subtyping these tumors. Moreover, the WHO classification alone does not accurately predict the risk of recurrence, as within subtypes patients have divergent prognoses.

The investigators will develop AI models using digital pathology and relevant clinical variables to improve the accuracy of histopathological classification of thymic epithelial tumors, and to better predict the risk of recurrence.

In this multicentric and international project three existing databases will be used from Rotterdam, Maastricht and Lyon. For all models one database will be used to build AI models, and the other two for external validation.

The ultimate goal of this project is to develop AI models that support the pathologist in correctly subtyping thymic epithelial tumors, in order to prevent patients from under- or overtreatment with adjuvant radiotherapy.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Participants with specific diagnoses are eligible for inclusion in the study. The eligible diagnoses include various subtypes of thymoma and thymic carcinoma, specifically:

  • Thymoma A

  • Thymoma AB

  • Thymoma B1

  • Thymoma B2

  • Thymoma B3

  • Thymic Carcinoma

Inclusion is based on a consensus diagnosis with a level of agreement less than 70%. This criterion is applied during the training phase of the model.

Recurrence Criteria:

Participants with a documented recurrence outcome within a 5-year period are considered eligible for this aspect of the study. This criterion is primarily applied during the validation phase.

Study Design

Total Participants: 1020
Treatment Group(s): 2
Primary Treatment: Recurrence Prediction Tool
Phase:
Study Start date:
August 01, 2023
Estimated Completion Date:
August 01, 2027

Connect with a study center

  • Erasmus MC

    Rotterdam, South Holland 3015 GD
    Netherlands

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.